AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 6886965
Drug: Alcohol (low
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alcohol (low dose)
Trial: 6886965
Drug: Alcohol (high
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alcohol (high dose)
Trial: 10638391
Drug: 60 mg
RxNorm normalized name: opium 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 mg oral dose of YM087
Trial: 10638391
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg i.v. dose of YM087
Trial: 7718321
Drug: Routine intravenous
RxNorm normalized name: Peace Out Acne Hero Routine KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine intravenous magnesium supplements
Trial: 1688914
Drug: Mild hypervolaemic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mild hypervolaemic haemodilution with hydroxyethyl starch (HES) combined with exercise (3 times weekly) for 6 weeks
Trial: 1688914
Drug: Ringer lactate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ringer lactate combined with exercise (3 times weekly) for 6 weeks
Trial: 1688914
Drug: Exercise alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exercise alone (3 times weekly)
Trial: 6586147
Drug: Levamisole (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levamisole (150 mg once weekly)
Trial: 6586147
Drug: Penicillamine (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Penicillamine (250 mg daily)
Trial: 15947609
Drug: Levofloxacin 500
RxNorm normalized name: levofloxacin 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levofloxacin 500 mg daily for 28 days
Trial: 8902991
Drug: Enoxaparin 20
RxNorm normalized name: enoxaparin
DrugBank: Enoxaparin (DB01225)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enoxaparin 20 mg once daily for 10 days
Trial: 8902991
Drug: Unfractionated heparin
RxNorm normalized name: Unfractionated heparin
DrugBank: Heparin (DB01109)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Unfractionated heparin 5000 IU twice daily for 10 days
Trial: 1831798
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg DMPA plus 100 mg TE monthly (Group I)
Trial: 1831798
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg DMPA plus 250 mg TE monthly (Group II)
Trial: 1831798
Drug: Both steroid
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both steroid regimens (Group I and Group II)
Trial: 6753611
Drug: Physostigmine (0.125
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physostigmine (0.125 mg, 0.25 mg, or 0.50 mg)
Trial: 6753611
Drug: Physostigmine (previously
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physostigmine (previously associated dose)
Trial: 26400993
Drug: Monovalent RV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monovalent RV vaccine (RV1) administered to infants
Trial: 25396674
Drug: Topical retapamulin
RxNorm normalized name: retapamulin Topical Ointment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical retapamulin ointment 1% (plus oral placebo), twice daily for 5 days
Trial: 25396674
Drug: Oral linezolid
RxNorm normalized name: Linezolid
DrugBank: Linezolid (DB00601)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral linezolid (plus placebo ointment) 2 or 3 times daily for 10 days
Trial: 20661659
Drug: BIB (6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BIB (6 months) followed by diet therapy (7 months)
Trial: 9641475
Drug: Aged garlic
RxNorm normalized name: Garlic 600 MG Oral Tablet [KYOLIC AGED GARLIC EXTRACT]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aged garlic extract (AGE) 7.2 g per day
Trial: 7865703
Drug: 2.4 g
RxNorm normalized name: ZINC OXIDE 12.4 g in 100 g TOPICAL CREAM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.4 g of piracetam
Trial: 7865703
Drug: 4.8 g
RxNorm normalized name: ALCOHOL 74.8 g in 100 g TOPICAL SWAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4.8 g of piracetam
Trial: 2770269
Drug: L-arginine and
RxNorm normalized name: Amino Acid, Amino Acids 5% (L-Arginine and L-Lysine) intravenous solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-arginine and L-ornithine (2 grams and 1 gram respectively)
Trial: 2770269
Drug: Placebo (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (600 mg of calcium and 1 gram of Vitamin C)
Trial: 143795
Drug: Live mumps
RxNorm normalized name: mumps virus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Live mumps vaccine from the L-3 strain, 1 dose containing 104HAdU50 of mumps virus
Trial: 28327932
Drug: Rolapitant 180
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rolapitant 180 mg oral
Trial: 26123682
Drug: Higher volume
RxNorm normalized name: VOLUME EXPANDERS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higher volume red wine (218 g alcohol/wk)
Trial: 26123682
Drug: Lower volume
RxNorm normalized name: flowers
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lower volume red wine (73 g alcohol/wk)
Trial: 22001171
Drug: Brand 1
RxNorm normalized name: Select Brand 12-Hour 0.05% Nasal Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brand 1 (Caballero Smooth Flavor; 0.89 mg ammonium per gram tobacco)
Trial: 22001171
Drug: Brand 2
RxNorm normalized name: Eagle Brand Medicated Oil
DrugBank: Eucalyptus oil (DB11114)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brand 2 (Gauloise Brunes; 3.43 mg ammonium per gram tobacco)
Trial: 19500510
Drug: CRRT without
RxNorm normalized name: threonine
DrugBank: Threonine (DB00156)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: CRRT without heparin
Trial: 19500510
Drug: CRRT with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CRRT with heparin
Trial: 16009365
Drug: Colesevelam HCl
RxNorm normalized name: colesevelam HCl
DrugBank: Colesevelam (DB00930)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Colesevelam HCl 3.0 g/d
Trial: 16009365
Drug: Colesevelam HCl
RxNorm normalized name: colesevelam HCl
DrugBank: Colesevelam (DB00930)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Colesevelam HCl 3.75 g/d
Trial: 11707825
Drug: 2 mg
RxNorm normalized name: iodine 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg lorazepam and 2 mg hydromorphone p.o. for the contralateral BMBA
Trial: 1591067
Drug: Intraperitoneal cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intraperitoneal cisplatin 90 mg/m2 plus intravenous etoposide (optimal dose 600 mg/m2)
Trial: 1591067
Drug: Intraperitoneal cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intraperitoneal cisplatin 90 mg/m2 plus intravenous etoposide (600 mg/m2)
Trial: 1591067
Drug: Intraperitoneal cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intraperitoneal cisplatin 90 mg/m2 plus intravenous etoposide (800 mg/m2)
Trial: 28066102
Drug: Tinidazole 500
RxNorm normalized name: tinidazole 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tinidazole 500 mg once daily + placebo for 5 days
Trial: 28066102
Drug: Metronidazole 500
RxNorm normalized name: metronidazole 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metronidazole 500 mg twice daily for 5 days
Trial: 23027821
Drug: α(1) adrenergic
RxNorm normalized name: aminophylline and adrenergics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: α(1) adrenergic agonist (phenylephrine, PE)
Trial: 23027821
Drug: α(2) adrenergic
RxNorm normalized name: aminophylline and adrenergics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: α(2) adrenergic agonist (clonidine, CL)
Trial: 9190848
Drug: dynorphin A(1-13)
RxNorm normalized name: Dynorphin a
DrugBank: Dynorphin (DB16146)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: dynorphin A(1-13) 0.1 mg/kg, 0.32 mg/kg, 1 mg/kg (15-min i.v. infusion)
Trial: 9190848
Drug: dynorphin A(1-13)
RxNorm normalized name: Dynorphin a
DrugBank: Dynorphin (DB16146)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: dynorphin A(1-13) 1 mg/kg (15-min i.v.) after morphine pretreatment
Trial: 9190848
Drug: morphine pretreatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: morphine pretreatment 45 mg/70 kg i.m.
Trial: 8398289
Drug: doxifluridine (dFUR)
RxNorm normalized name: Trifluridine
DrugBank: Doxifluridine (DB12947)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: doxifluridine (dFUR) 4000 mg/m2 daily for 5 days every 28 days
Trial: 8398289
Drug: fluorouracil (FU)
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: fluorouracil (FU) 500 mg/m2 daily for 5 days every 28 days
Trial: 3299905
Drug: Ivermectin (12
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ivermectin (12 mg single oral dose)
Trial: 3299905
Drug: Diethylcarbamazine (DEC)
RxNorm normalized name: diethylcarbamazine
DrugBank: Diethylcarbamazine (DB00711)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Diethylcarbamazine (DEC) (50 mg daily for two days and 100 mg twice daily for the following six days, total 1.3 g in eight days)
Trial: 18279685
Drug: 7-day hormone-free
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 7-day hormone-free interval (HFI) with placebo
Trial: 18279685
Drug: 84/7-day cycle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 84/7-day cycle of 150 mcg LNG/30 mcg EE for 84 days followed by 7 days of 10 mcg EE
Trial: 18279685
Drug: 21/7-day cycle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 21/7-day cycle of 150 mcg LNG/30 mcg EE for 21 days followed by 7 days of placebo
Trial: 10367614
Drug: Counterdependency Scale
RxNorm normalized name: wing scale pollen extract
DrugBank: Atriplex canescens pollen (DB10767)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Counterdependency Scale (CDS) administered to patients with chronic pain
Trial: 8897388
Drug: CHO‐7 (7%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CHO‐7 (7% carbohydrate‐electrolyte solution)
Trial: 8897388
Drug: CHO‐0/21 (placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CHO‐0/21 (placebo for first 90 min then a 21% glucose solution)
Trial: 1825972
Drug: 300 mg
RxNorm normalized name: rutin 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg etodolac twice daily (n = 31)
Trial: 1825972
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg indomethacin 3-times daily (n = 33)
Trial: 19886982
Drug: Daily dosing
RxNorm normalized name: Osmolex 322 MG Daily Dosing Pack
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily dosing of isoniazid
Trial: 19886982
Drug: Three times
RxNorm normalized name: WELLBUTRIN 100 MG Oral Tablet, Three Times Daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three times a week dosing of isoniazid
Trial: 19886982
Drug: Both dosing
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both dosing schedules (daily and three times a week)
Trial: 9221683
Drug: Aspirin (125
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin (125 mg daily)
Trial: 9221683
Drug: Pentoxifylline (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pentoxifylline (300 mg daily)
Trial: 8424516
Drug: Intravenous glucose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous glucose at 10 g/h during the operation
Trial: 23331240
Drug: Triple antibiotic
RxNorm normalized name: Triple Antibiotic
DrugBank: Polymyxin B (DB00781)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Triple antibiotic paste (TAP)
Trial: 20533106
Drug: 7-day therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7-day therapy with lansoprazole (30 mg b.i.d.), levofloxacin (500 mg o.i.d.), and amoxicillin (1000 mg b.i.d.)
Trial: 20533106
Drug: 14-day therapy
RxNorm normalized name: tetracycline
DrugBank: Tetracycline (DB00759)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 14-day therapy with lansoprazole (30 mg b.i.d.), levofloxacin (500 mg o.i.d.), and amoxicillin (1000 mg b.i.d.)
Trial: 12684649
Drug: Pegfilgrastim (6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pegfilgrastim (6 mg or 100 microg/kg, single SC injection on day 2 of chemotherapy cycle)
Trial: 12684649
Drug: Filgrastim (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Filgrastim (5 microg/kg/day, daily SC injections until ANC > or =10 x 10(9)/l or for up to 14 days)
Trial: 8574437
Drug: Nedocromil sodium
RxNorm normalized name: Nedocromil Sodium
DrugBank: Nedocromil (DB00716)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nedocromil sodium (4 mg, two inhalations) administered 30 minutes before exercise
Trial: 30616380
Drug: Cisplatin plus
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cisplatin plus PUFAs (3600 mg/day for three courses, each course included 3 weeks)
Trial: 28219692
Drug: Rivaroxaban 10
RxNorm normalized name: rivaroxaban 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rivaroxaban 10 mg oral once daily for 45 days
Trial: 28219692
Drug: Fondaparinux 2.5
RxNorm normalized name: FONDAPARINUX 2.5MG/0.5ML INJ SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fondaparinux 2.5 mg subcutaneous once daily for 45 days
Trial: 22136960
Drug: n3-LCPUFA (900
FDA approved: no
EMA approved: no
PMDA approved: no
Description: n3-LCPUFA (900 mg daily)
Trial: 21318452
Drug: Low-dose omega
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose omega 3 fatty acids (1 gram of fish oil capsule containing 300 mg of eicosapentaenoic acid and docosahexaenoic acid daily for 6 months
Trial: 11292954
Drug: MPFF (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MPFF (2 tablets daily for 24 weeks)
Trial: 11292954
Drug: Control (standard
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (standard compressive therapy plus external treatment)
Trial: 2575375
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of BRCR and EXP
Trial: 2575375
Drug: All treatments
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All treatments (BRCR, EXP, Combination)
Trial: 12879276
Drug: Single 5-ml
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single 5-ml intramuscular injection of 250 mg fulvestrant
Trial: 12879276
Drug: Two 2.5-ml
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two 2.5-ml intramuscular injections with a total of 250 mg fulvestrant
Trial: 1610026
Drug: Slo-bid 800
RxNorm normalized name: Slo-bid
DrugBank: Theophylline (DB00277)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Slo-bid 800 mg once-a-day in the morning for 2 weeks
Trial: 1610026
Drug: Slo-bid 800
RxNorm normalized name: Slo-bid
DrugBank: Theophylline (DB00277)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Slo-bid 800 mg once-a-day in the evening for 2 weeks
Trial: 27870481
Drug: PF-04937319 (split-dose,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PF-04937319 (split-dose, 150+100 mg)
Trial: 27870481
Drug: PF-04937319 (once
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PF-04937319 (once daily, 300 mg)
Trial: 20878044
Drug: Twice/week training
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Twice/week training (group 1)
Trial: 8646870
Drug: Fluticasone propionate
RxNorm normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Fluticasone propionate cream, 0.05%
Trial: 8646871
Drug: Hydrocortisone-17-butyrate cream,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrocortisone-17-butyrate cream, 0.1%
Trial: 7948154
Drug: 0.5% podophyllotoxin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5% podophyllotoxin solution
Trial: 22685164
Drug: Oral nutritional
RxNorm normalized name: Ocean Blue Nutritionals Omega-3 1450 Oral Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral nutritional supplementation (ONS) - 18-24 g protein and 500 kcal per day
Trial: 18254433
Drug: Mentoring group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mentoring group (tutoring conversational skills to ESL students for 1 hour twice per week for 12 weeks)
Trial: 9663841
Drug: Dual or
RxNorm normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dual or triple combination therapies including one proton pump inhibitor (30 mg/day lansoprazole or 20 mg/day omeprazole) and one or two antibiotics (500 mg AMOX, 200 mg CLAR or 250 mg MNZ twice a day)
Trial: 28506664
Drug: Heliox (70:30)
RxNorm normalized name: Helixate
DrugBank: Helium (DB09155)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Heliox (70:30) via high flow nasal cannula at 8 L/min for 24 hours
Trial: 28506664
Drug: Air–oxygen mixture
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Air–oxygen mixture 30% via high flow nasal cannula at 8 L/min for 24 hours
Trial: 18576906
Drug: Simvastatin 20
RxNorm normalized name: simvastatin 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simvastatin 20 mg/day in HIV-infected patients
Trial: 18576906
Drug: Simvastatin 20
RxNorm normalized name: simvastatin 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simvastatin 20 mg/day in HIV-negative patients (control)
Trial: 1709566
Drug: Inert placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inert placebo tablet
Trial: 1709566
Drug: No hypnotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No hypnotic
Trial: 6130752
Drug: Imipramine (up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imipramine (up to 200 mg/day for 28 weeks)
Trial: 31520730
Drug: Pancreatic enzyme
RxNorm normalized name: Pancreatic enzyme
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pancreatic enzyme replacement therapy (PERT) - 40,000 IU pancreatin, 3 times daily during meals for 3 months, n = 151
Trial: 31236672
Drug: Combined therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined therapy (Topical calcipotriol + NB‐UVB)
Trial: 28642024
Drug: Active rTMS
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active rTMS treatment (n = 38)
Trial: 28642024
Drug: Sham treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham treatment (n = 37)
Trial: 16786822
Drug: Cognitive-behavioral treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-behavioral treatment (CBT) for anxiety
Trial: 21477035
Drug: Whitening priming
RxNorm normalized name: monofluorophosphate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Whitening priming agent (Power Swabs) applied prior to whitening treatment.
Trial: 21477035
Drug: No whitening
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No whitening priming agent applied (control group).
Trial: 14692438
Drug: Granisetron treatment
RxNorm normalized name: Granisetron
DrugBank: Granisetron (DB00889)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Granisetron treatment
Trial: 10758440
Drug: Dolasetron (12.5,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dolasetron (12.5, 25, 50, or 100 mg)
Trial: 10758440
Drug: Dolasetron (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dolasetron (all doses combined)
Trial: 9257201
Drug: Dolasetron (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dolasetron (all doses)
Trial: 1417173
Drug: Intraportal glucose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraportal glucose infusion
Trial: 8936492
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no glucose infusion)
Trial: 3972231
Drug: Low doses
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low doses of interferon (36 and 50 X 10(6) U)
Trial: 17668530
Drug: Combined therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined therapy of anti-inflammatory dose doxycycline (40-mg doxycycline, usp monohydrate controlled-release capsules) and topical metronidazole gel 1%
Trial: 17668530
Drug: Topical metronidazole
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical metronidazole gel 1%
Trial: 15383192
Drug: Ezetimibe 10
RxNorm normalized name: ezetimibe 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ezetimibe 10 mg/day + statin
Trial: 26894175
Drug: Topical 0.2%
RxNorm normalized name: coal tar topical 0.2% topical soap
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical 0.2% hyaluronic acid therapy for 14 days
Trial: 26894175
Drug: Topical placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical placebo application for 14 days
Trial: 18973518
Drug: Phytate-containing mouthwash
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phytate-containing mouthwash (20 mL, twice daily for 1 min)
Trial: 17577007
Drug: Placebo or
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo or other treatment
Trial: 16342649
Drug: Aspirin (81
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin (81 mg orally) from the start of DVd-T treatment (group 1)
Trial: 16342649
Drug: Aspirin (81
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin (81 mg orally) after the start of DVd-T treatment (group 2)
Trial: 16342649
Drug: No aspirin
RxNorm normalized name: XS No Aspirin PR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No aspirin (group 3)
Trial: 1900094
Drug: Naloxone (1.6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naloxone (1.6 mg/h x 4 h preceded by 1.6 mg iv bolus)
Trial: 7128220
Drug: Theophylline (low
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Theophylline (low dose: 8.7-13.0 micrograms/ml)